Table 1.
Patient demographics and baseline clinical characteristics in the full study population and 6-month follow-up sample
| All patients | 6-month follow-up patients* | |
|---|---|---|
| N = 9753 | N = 4437 | |
| Age, mean (SD) | 46.5 (12.1) | 46.7 (11.8) |
| Age category, n (%) | ||
| 18–34 | 1550 (15.9) | 655 (14.8) |
| 35–44 | 2458 (25.2) | 1104 (24.9) |
| 45–54 | 3134 (32.1) | 1497 (33.7) |
| 55–64 | 2180 (22.4) | 1000 (22.5) |
| 65–74 | 353 (3.6) | 148 (3.3) |
| 75+ | 78 (0.8) | 33 (0.7) |
| Sex (female), n (%) | 8329 (85.4) | 3808 (85.8) |
| Geographic region, n (%) | ||
| Northeast | 1047 (10.7) | 507 (11.4) |
| Midwest | 2134 (21.9) | 934 (21.1) |
| South | 2998 (30.7) | 1287 (29.0) |
| West | 1373 (14.1) | 633 (14.3) |
| Unknown | 2201 (22.6) | 1076 (24.3) |
| Year of index date | ||
| 2018 | 6185 (63.4) | 4437 (100.0) |
| 2019 | 3568 (36.6) | 0 (0.0) |
| Comorbidities | ||
| Asthma | 727 (7.5) | 174 (3.9) |
| Hypertension | 1790 (18.4) | 457 (10.3) |
| Acute myocardial infarction | 37 (0.4) | 8 (0.2) |
| Ischemic stroke | 77 (0.8) | 23 (0.5) |
| Constipation | 306 (3.1) | 76 (1.7) |
| Irritable bowel syndrome | 232 (2.4) | 48 (1.1) |
| Complications of constipation | 187 (1.9) | 44 (1.0) |
| Anxiety | 2125 (21.8) | 646 (14.6) |
| Depression | 1606 (16.5) | 500 (11.3) |
| Other (non-migraine) headaches | 2829 (29.0) | 810 (18.3) |
| Low back pain | 1511 (15.5) | 463 (10.4) |
| Osteoarthritis/spondylosis | 1411 (14.5) | 393 (8.9) |
| Fibromyalgia | 549 (5.6) | 171 (3.9) |
| No comorbidities | 2981 (30.6) | 2056 (46.3) |
| Migraine characteristics | ||
| Migraine with aura, including persistent aura | 2611 (26.8) | 915 (20.6) |
| Migraine with aura, excluding persistent aura | 2530 (25.9) | 890 (20.1) |
| Chronic migraine | 6274 (64.3) | 2904 (65.4) |
| Menstrual migraine | 259 (2.7) | 103 (2.3) |
| Status migrainosus | 2607 (26.7) | 1103 (24.9) |
SD standard deviation
*Comorbidities and migraine characteristics for the 6-month follow-up period were based on a 6-month baseline period whereas the same elements for all patients were based on a 12-month baseline period